CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
The distinction between Sézary syndrome (SS) and benign erythrodermic inflammatory diseases (EID) is difficult to make both clinically and on skin biopsies, since histomorphology can provide nonspecific results. New markers of circulating malignant Sézary cells have been recently described, especially CD158k/KIR3DL2 and T-plastin, but it has not been yet determined whether they could help in the diagnosis of erythroderma in skin samples. In this study, 13 frozen skin specimens from 10 SS patients and 26 from EID were analyzed for CD158k/KIR3DL2 expression using immunohistochemistry with AZ158 mAb, which also recognizes the monomeric CD158e/KIR3DL1 receptor. Although positive in all SS samples, immunohistochemistry appeared to not reliably discriminate between SS and EID. Therefore in all samples disclosing a significant staining with AZ158 mAb, CD158k/KIR3DL2, CD158e/KIR3DL1 and T-plastin mRNA expression were analyzed on the same skin specimen using conventional and/or quantitative real-time reverse transcription (RT)-PCR. Interestingly, only CD158k/KIR3DL2 transcripts were found to be significantly overexpressed in skin biopsies from patients with SS (P<0.0001), including when normalization to CD3 expression was achieved (P=0.0003). In light of these findings, CD158k/KIR3DL2 transcripts appear to be a unique molecular marker of SS in skin samples, allowing differential diagnosis with benign EID in routine practice.
Ortonne
Nicolas
N
Department of Pathology, AP-HP, groupe hospitalier Henri Mondor-Albert Chenevier, Créteil, France. nicolas.ortonne@hmn.aphp.fr
Le Gouvello
Sabine
S
Mansour
Hicham
H
Poillet
Catherine
C
Martin
Nadine
N
Delfau-Larue
Marie-Hélène
MH
Leroy
Karen
K
Farcet
Jean-Pierre
JP
Bagot
Martine
M
Bensussan
Armand
A
D000368:Aged; D017398:Alternative Splicing; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D015925:Cryopreservation; D003873:Dermatitis, Exfoliative / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D008875:Middle Aged; D010750:Phosphoproteins / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D054343:Receptors, KIR2DL2 / Q000235:genetics* / Q000378:metabolism; D012751:Sezary Syndrome / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; C515077:KIR2DL2 protein, human; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D010750:Phosphoproteins; D012333:RNA, Messenger; D054343:Receptors, KIR2DL2; C026742:plastin
Blood. 2000 Aug 1;96(3):1056-63
10910922
Blood. 2007 Jun 1;109(11):5064-5
17522341
Br J Dermatol. 2001 Jan;144(1):125-35
11167693
J Immunol. 2001 Feb 15;166(4):2487-94
11160309
Blood. 2001 Mar 1;97(5):1388-91
11222384
J Am Acad Dermatol. 2001 Mar;44(3):456-61
11209115
Am J Clin Pathol. 2001 Jun;115(6):885-92
11392886
J Invest Dermatol. 2002 Jul;119(1):193-6
12164946
J Pathol. 2003 Jan;199(1):77-83
12474229
Blood. 2003 Feb 15;101(4):1513-9
12393503
J Exp Med. 2003 Jun 2;197(11):1477-88
12782714
Mod Pathol. 2003 Sep;16(9):857-62
13679448
Cancer Res. 2003 Nov 1;63(21):7122-7
14612505
J Invest Dermatol. 2004 Mar;122(3):820-3
15086570
Genome Biol. 2004;5(8):R59
15287981
Cancer Res. 2004 Aug 15;64(16):5578-86
15313894
Br J Dermatol. 2004 Sep;151(3):546-56
15377339
Blood. 1985 Aug;66(2):358-66
2410067
J Am Acad Dermatol. 1992 Oct;27(4):589-93
1357011
J Biol Chem. 1993 Feb 5;268(4):2781-92
8428952
J Invest Dermatol. 1994 Jul;103(1):34-41
8027579
Blood. 1995 Jul 1;86(1):305-10
7795237
J Invest Dermatol. 1995 Jul;105(1):56-61
7542297
Genome Res. 1996 Oct;6(10):995-1001
8908519
Immunol Rev. 1997 Feb;155:105-17
9059886
Ann Hematol. 1997 Mar;74(3):123-30
9111425
Br J Dermatol. 1997 Nov;137(5):673-9
9415223
Immunity. 1997 Dec;7(6):753-63
9430221
Int J Dermatol. 1998 Feb;37(2):104-7
9542663
Arch Dermatol. 1999 Feb;135(2):158-62
10052400
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3769-74
10097112
J Clin Pathol. 2004 Dec;57(12):1325-8
15563677
Mol Biol Cell. 2005 Mar;16(3):1366-77
15647371
Blood. 2005 May 15;105(10):3768-85
15692063
BMC Dermatol. 2005;5:5
15882451
Br J Dermatol. 2005 Jul;153(1):1-5
16033336
Int J Dermatol. 2005 Sep;44(9):731-5
16135140
Cancer Res. 2005 Sep 15;65(18):8101-10
16166283
J Immunol. 2006 Jan 1;176(1):652-9
16365461
Blood. 2006 Jan 1;107(1):381-8
16160005
Blood. 2006 Apr 15;107(8):3189-96
16403914
Blood. 2006 May 15;107(10):4030-8
16418328
Blood. 2000 Nov 1;96(9):2987-92
11049975